What is Chimeric Therapeutics?
Founded in 2020, Chimeric Therapeutics operates as a specialized biotechnology firm dedicated to the rigorous development of innovative cancer therapies. The company functions at the intersection of scientific research and clinical application, focusing on novel therapeutic modalities that target unmet medical needs. By maintaining a robust portfolio of oncology-focused assets, the organization collaborates extensively with healthcare institutions to transition experimental treatments through the complex phases of clinical trials. Its market position is defined by a strategic focus on high-impact research, positioning it as a key player in the Australian and global biotech ecosystem.
How much funding has Chimeric Therapeutics raised?
Chimeric Therapeutics has raised a total of $53.5M across 3 funding rounds:
Stock Offering
$35M
Share Placement
$10.1M
Stock/Share Issuance
$8.4M
Stock Issuance/Offering (2021): $35M, investors not publicly disclosed
Share Placement (2023): $10.1M, investors not publicly disclosed
Stock/Share Issuance (2025): $8.4M, investors not publicly disclosed
Key Investors in Chimeric Therapeutics
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Chimeric Therapeutics?
With the recent injection of capital, Chimeric Therapeutics is well-positioned to scale its operational capacity and expedite its clinical trial milestones. The company's forward-looking strategy involves deepening its investment in proprietary research platforms and expanding its collaborative network with leading medical research centers. As the firm navigates the next phase of its growth, the focus will likely remain on de-risking its pipeline and achieving regulatory milestones that validate its therapeutic candidates. This strategic trajectory suggests a transition toward more advanced clinical development stages, potentially enhancing the firm's valuation and long-term market influence in the oncology sector.
See full Chimeric Therapeutics company page
